

# PROFERRED PAPER SESSION

## SARCOMA


**Abstracts no. 3580, 3590, 3600**

Jayesh Desai

Medical Oncologist

Peter MacCallum Cancer Centre/

Royal Melbourne Hospital



Abstract 3580

# Chemo-responsiveness predictive biomarker discovery for osteosarcoma using microRNA-microarray

D. Kubota, Y. Suehara, E. Kobayashi, K. Kaneko, A. Kawai, T. Kondo

Division of Musculoskeletal Oncology, National Cancer Center , Tokyo, Japan

Department of Orthopedic Surgery, Juntendo University, Tokyo, Japan




National Cancer Center Hospital


# miRNAs

- MicroRNAs (miRNAs) are single-stranded noncoding RNAs involved in various biological processes through post-transcriptional modifications
- There are known to be at least 4000 miRNAs in human genome
- Regulate approx 50% of human genes. Each miRNA likely controls hundreds of gene transcripts
- Can have an oncogenic (overexpressed) or tumour suppressive role (underexpressed), hence their interest as a biomarker

# miRNAs in Osteosarcoma



# Work flow




- Identify potential miRNAs based on chemo response
- Validation
- Functional Study
- Large scale validation

# Functional study


## Cytotoxicity

MTX




- Osteosarcoma cell line (MNNG/HOS, 143B, and MG63)
- The  $IC_{50}$  values were inspected before and after transfection of miR-125b and miR-100.
- Over expression of miRNAs resulted increasing drug resistance for MTX/DOX/CDDP.

DOX



CDD



# miRNAtarget

- miRNA targets database




miRBase

- miR-125b: **P53, BCL-2 Family**

- Bak1 (apoptosis)
- TP53 (apoptosis)
- PUMA (apoptosis)

- miR-100: **Rb Family**

- CTDSPL (cell cycle)



# Conclusion and Next Steps

- We identified the miRNAs as predictive biomarker of chemo-response in osteosarcoma.
- miR-125b and miR-100 were up-regulated in non-responders.
- Cytotoxicity assay suggested these miRNAs may contribute to a broad spectrum of chemo-resistance mechanism.
- miR-125b and miR-100 targeted p53 and Rb pathway. These miRNAs may promote cell proliferation, and inhibit drug-induced apoptosis.
- ROC curve analysis revealed the high predictive ability of these miRNAs.

- Further miRNAs identified in OS
- May have role as a **Predictive Biomarker**
- Single vs multiple miRNAs?
- Identified through functional screens, and then validated clinically and preclinically

## Future Studies

- Prospective validation in large clinical trials
- ?role in modifying response to all 3 agents
- ?other measures of miRNAs eg circulating levels



# A Whole Genome Approach to Better Understand the Link Between Kaposi's Sarcoma-Associated Herpesvirus and Human Cancers

**Abstract 3590**

ESMO Asia – Dec 19<sup>th</sup> 2015

Coralie Viollet, PhD

HIV and AIDS Malignancy Branch, National Cancer Institute, NIH – USA

Wellcome Trust Centre for Human Genetics, University of Oxford – UK





**wellcome**trust

Fellow

# Overview

## KSHV and Hypoxia

- KSHV-associated malignancies, KS and PEL, arise in settings of relatively low oxygen concentrations (hypoxia)
- Hypoxia can activate KSHV production via a transcription factor called HIF (Hypoxia-inducible factor)



## KSHV Infected Cells:

Whole genome approach to explore genes affected by hypoxia



# Results

miR-210, a microRNA involved in hypoxia and cancer, was increased by both hypoxia and KSHV infection

- miR-210 is a predominant microRNA up-regulated by hypoxia in a variety of cell lines
- By knocking down a variety of repressors, miR-210 induces angiogenesis, cell survival and cell proliferation
- miR-210 known targets are ISCU (mitochondrial metabolism) and EFNA3 (angiogenesis inhibitor)

- miR-210 is up-regulated by hypoxia, but also by KSHV infection – even in normoxic conditions

- miR-210 expression is inversely correlated to its target expression (ISCU)




- Hypoxia drastically changes expression profile of KSHV-infected cells
- KSHV infection induces miR-210, a key hypoxia-regulated miRNA involved in cancer
- However, viral miRNAs don't change in response to hypoxia

# Additional information

## miRNA-210

- miR-210 targets and their biological functions:
  - miR-210 induces cell survival and increases cell proliferation
  - miR-210 induces angiogenesis
  - miR-210 represses mitochondrial metabolism
  - miR-210 stalls DNA repair



miR-210: the Master Hypoxamir, Chan et al. 2011

# Conclusions Abstracts 3580 and 3590

- Potential value in using miRNAs to better understand the complexities of tumorigenesis
- Explore Utility of miRNAs as both a biomarker (predictive and prognostic) and in understanding pathogenic links to disease
- Potential value as a circulating biomarker
- Challenges will be in understanding their context and functional significance in individual tumour types

# Clinicopathological and functional analyses of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors

Yoshiyuki Suehara<sup>1</sup>, Midori Ishii<sup>1,2</sup>, Keisuke Akaike<sup>1,2</sup>, Kenta Mukaihara<sup>1,2</sup>, Daisuke Kubota<sup>1</sup>, Taketo Okubo<sup>1</sup>, Tatsuya Takagi<sup>1</sup>, Takashi Yao<sup>2</sup>, Kazuo Kaneko<sup>1</sup>, Tsuyoshi Saito<sup>2</sup>

1: Department of Orthopaedic Surgery, Juntendo University School of Medicine

2: Department of Human Pathology, Juntendo University School of Medicine

# Overview

- Mutations in *PPP2R1A* only recently described (2007)
  - Most commonly reported in Ovarian and Uterine Ca
  - Only 169 cases in Cosmic database
  - Reports in other tumours, eg. prostate
- Aimed to explore *PPP2R1A* in GIST
  - 94 Patients
  - All primary tumours, i.e. pre-treatment
  - Why?

# RESULTS

The relationship between *PPP2R1A* mutations and driver mutations in 17 GIST cases

⊗ *PPP2R1A* mutated GISTs ( 17 cases )

⊗ <i>KIT</i>	13 cases ( 76.5% )
⊗ <i>PDGFR<math>\alpha</math></i>	2 cases ( 11.8% )
⊗ <i>KRAS</i>	1 case ( 5.9% )
⊗ <i>KIT/PDGFR<math>\alpha</math>/KRAS</i> negative	1 case


- 17 (18.1%) of 94 GIST cases harbored *PPP2R1A* mutations.
- Not isolated to WT patients
- Univariate analysis: Correlated with tumour grade/agressiveness, and overall outcomes
- Multivariate analysis with larger numbers would be very useful



# RESULTS: Functional Significance

## Human phospho-kinase array analysis

using two GIST cell lines which were transduced with Val201Ala (*PPP2R1A*-T602C) or Glu238Lys (*PPP2R1A*-G712A)



- Limited data in gynaecological cancer models suggesting function through AKT
- Transduced GIST cell lines
  - ?unsure how extensive their phospho-protein analysis was

# Conclusions and Next Steps

- Novel and very interesting study
- Co-existing mutations in reasonable percentage of GIST cases, co-existing with other key drivers
- Value in
  - Better understanding the utility of PPP2R1A as a biomarker
  - Exploring patient cohorts post-TKI therapy
  - Understanding functional effects in more detail
  - Exploring mechanisms to target these changes